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The ability of natural killer (NK) cells to provide protection against myeloid leukemia has
been demonstrated in clinical settings. However, whether NK cells play a role in the clinical
course of solid tumors is debated. The controversy surrounding the role of NK cells is
due, at least in part, to the limited extent of NK cell infiltration found in the tumor bed.
Inactivation of NK cells may explain the shortage of NK cells in the microenvironment of
colorectal cancer (CRC). Upon NK cell/tumor cell interaction, tumor cells may escape NK
cells by creating an immunosuppressive microenvironment, which possibly affects T-cells
as well. Such an immunosuppressive microenvironment would hamper the functions of
NK and T-cell and reduce NK and T-cell interactions. CRC patients with levels of tumor
NK cell infiltration suitable for statistical analysis have been identified. The infiltration
of the CRC microenvironment by NK cells, in combination with CD8+ T-lymphocytes,
has been shown to enhance the prognosis of CRC patients. Here, we discuss the
clinicopathological role of NK cells in CRC, and present clinical data indicating a potential
supporting role for NK cells in the anti-CRC effects of CD8+ T-cells.
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Human Natural Killer Cells
Natural killer (NK) cells are cytotoxic, with proven antitumor activity in mouse models andmyeloid
leukemia. Recent evidence strongly suggests that the antitumor activity of NK cells is not solely
due to their cytotoxic function but also relies on the ability of NK cells to shape a proinflammatory
microenvironment. NK cells are defined by three main characteristics: (i) a lack of a recombinant-
activating gene (RAG)-dependent rearranged antigen receptor, (ii) lymphoid morphology, and (iii)
expression of myeloid cell surface markers. NK cells belong to group I members of innate lymphoid
cells. They are well-known producers of interferon gamma (IFN-γ) and proinflammatory cytokines,
but they are unable to synthesize TH17 and TH2 cell-associated cytokines. Based on the intensity
of expression of the neural cell adhesion molecule 1 (NCAM1), known as CD56 molecule, on the
cell surface, two subsets of NK cells have been identified. The first subset, referred to as CD56dim
NK cells, is characterized by low levels of CD56 expression in about 90% of Fcγ receptor IIIA
(CD16)high NK cells. The second subset, referred to as CD56bright NK cells, is characterized by high
levels of CD56 expression in about 10% of CD16-negative NK cells (1). The latter populationmainly
produces regulatory cytokines, and the former mediates natural and antibody-dependent cellular
cytotoxicity (ADCC). CD56 is a broadmarker ofNK cells; however, it is also expressed byNKT-cells,
(2) dendritic cells, and a small subset of human monocytes (3). Thus, the CD56 antigen is not an
exclusive marker for phenotypic and functional characterization of human NK cells.
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Natural killer cells originate in bone marrow from CD34+Lin-
CD45RA+CD10+ common lymphoid progenitor cells. In the
absence of bone marrow stroma, the differentiation of CD34+
cells into NK cells requires interleukin-2 (IL-2) or IL-15 and
stem cell factors. IL-15 appears to be the most relevant cytokine
for NK cell differentiation, and is synthesized by bone marrow
stromal cells (4). In the early differentiation stage, NK cells have
a CD56bright CD94/NKG2A+CD16 granzyme A+ phenotype.
Early differentiated NK cells have a defective cytotoxic function
but can exert antiproliferative activity against tumor cells (5).
Natural killer-cell-mediated cytotoxicity is regulated by a bal-
ance between signals generated by natural and accessory trigger-
ing receptors and inhibitory receptors. NK cells use an array of
cytotoxic receptors capable of recognizing cell surface ligand(s)
expressed on tumor and normal cells. Some of these recep-
tors, including NKp30, NKp44, and NKp46 (6), are preferentially
expressed on NK cells, and are involved in the recognition of
leukemia and solid tumor cells. CD16 is also a primary NK
activating receptor that mediates both natural cytotoxicity by
unknown ligand(s) and ADCC (7). The role of the CD16 antigen
in tumor immunotherapy has been the focus of recent atten-
tion in the field of tumor immunotherapy, as clinically relevant
therapeutic monoclonal antibodies (mAbs) exert their antitumor
function through an ADCC-mediated mechanism. NKG2D is
another critical receptor mediating NK cell killing of solid tumor
cells. It binds to the major histocompatibility complex class I
polypeptide-related sequence A/B (MICA/B) and to the UL16
binding protein expressed on solid tumor cells and leukemic
cells, respectively. DNAX accessory molecule-1 (DNAM-1) is an
additional activating receptor that binds to Nectin-2 and the
poliovirus receptor, CD155/PVR. Nectin-2 is expressed in cell
junctions of non-malignant cells, and CD155/PVR is expressed
by some myeloid and CD4+ T-cells. Nectin-2 and CD155/PVR
have been identified in a variety of solid tumor cells. NKp80 is
the ligand of the activation-induced C-type lectin, and 2B4, which
recognizes the CD48 antigen, are involved in the recognition of
leukocytes and endothelial, leukemia, and solid tumor cells (8).
Additional cell surface molecules, such as CD2, CD69, CD44
(9), and CD38 (10), are involved in NK cell activation. These
molecules have been identified with conventional mAbs, which
redirect NK cell cytotoxicity against Fc receptor-positive cells.
Bispecific antibodies have been utilized for redirecting NK cells
against Fc receptor-negative cells.
Natural killer cells use polymorphic killer inhibitory recep-
tors (KIRs) to prevent autoimmunity. Under these circumstances,
full engagement of KIRs with human leukocyte antigen (HLA)
class I leads to the inhibition of NK-cell-mediated cytotoxicity.
Human KIRs are separated into two groups: immunoglobulin-
like receptors and heterodimers, characterized by an invariant
protein termed CD94 and a variable C-type lectin subunit, also
known as NKG2 (CD94/NKG2). KIRs have intracellular tyrosine
inhibitorymotifs in their cytoplasmic domains. To date, investiga-
tors have identified 14 KIRs. Early in 2000, a dedicated committee
established a useful and versatile nomenclature system for KIRs.
The digit following the acronym (KIR) represents the number of
the Ig-like domains in the molecule. The letter “D” stands for
the domain, and the letter “L” and “S” stand for long and short
cytoplasmic tails, respectively. The last digit indicates the gene that
codes for the protein. Inhibitory KIRs possessing two or three Ig-
domains are referred to as KIR2DL andKIR3DL, respectively. The
former has specificity for HLA-C, and the latter has specificity
for HLA-A/B. Due to polymorphisms at positions 77 and 80 in
the α1-domain of the β chain, KIR2DL1 and KIR2DL2/KIR2DL3
recognize different groups of HLA-class I alleles. KIR2DL1 binds
to HLA class I alleles, defined as C2 (Cw2, Cw4, Cw5, and Cw6).
KIR2DL2 and KIR2DL3 bind to HLA-class I alleles, designated
as C1 (Cw1, Cw3, Cw7, Cw8). KIR3DL2 binds to HLA-A3 and
HLA-A1, and KIR3DL1 interacts with the HLA-Bw4 determi-
nant. Upon specific binding with one or a group of HLA class I
molecules, these receptors recruit tyrosine phosphatases, leading
to inhibition of cellular functions (11). “L” KIRs are flanked by
short “S” KIRs. “S” KIRs are “L” KIR homologous in the extracel-
lular region, but they possess a short intracellular tail that lacks
intracellular tyrosine inhibitory motifs, and are associated with
a protein tyrosine-kinase-binding protein also known as DAP12.
These molecules can function as activating receptors.
NK and T-Cell Cooperation in the Clinical
Development of Colorectal Cancer
With the exception of cancers developing in colonic tissues
affected by inflammatory bowel diseases, there is a consensus that
inflammation may play a role in the clinical course of colorectal
cancer (CRC). Infiltration of the CRC tumor microenvironment
by tumor-associated macrophages (12–14), CD8+ T-cells (15),
and CD4+ regulatory T-cells (16) is an independent favorable
prognostic factor for CRC. Among solid tumors, the protective
role of tumor-associatedmacrophages in CRC is unique and likely
reflects an altered balance between M1 andM2macrophages. M2
macrophages promote tumor progression by enhancing angiogen-
esis and inhibiting an immune response against tumors, whereas
M1 macrophages promote a proinflammatory microenvironment
by releasing IL-1β, IL-6, IL-12, and tumor necrosis factor alpha
(TNF-α). Indeed, a recent study demonstrated that the presence
of high M1 macrophage infiltration in the CRC tumor microen-
vironment was associated with improved overall survival (OS) in
a stage-dependent manner (17).
To date, there is conflicting information about the clinical
relevance of NK cell infiltration in CRC. Although a number of
tumor cells of different histological origin express high levels of
the NKG2D ligand complex MICA/B, NK cells in the solid tumor
microenvironment are barely detectable. A paucity of NK cells in
the solid tumor milieu represents the main hurdle to determine
whether NK cells play a role in the clinical course of solid tumors
(18). Recently, we and other investigators have focused on the
investigation of the clinical impact of NK cell infiltration on the
prognosis of CRC. An early study involving 157 patients showed
that patients with tumor-node-metastasis stage III disease with
extensive CD57+ NK cell infiltration survived longer than those
with low infiltration (19). In a study of 93 patients, Menon et al.
showed that patients with elevated levels of CD56+ or CD57+
NK cell infiltration had longer disease-free survival (DFS) than
those with lower levels of infiltration. Marechal et al. examined
theCD56+ cell content of 68 primary tumors ofCRCpatientswith
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tumor-node-metastasis stage IV. In their study, the patients were
treated with chemotherapy, with or without cetuximab, a thera-
peutic chimericmAb. They concluded that the presence of CD56+
cells in the tumormilieu was an independent favorable prognostic
factor, and that it was associated with prolonged progression-
free survival only in the group of cetuximab-treated patients. An
additional study byGulubova et al. of 34CRCpatients showed that
NK cell infiltration was decreased in livers harboring metastases
as compared to that of normal organs. However, no information
about the DFS survival and OS of the CRC patients was provided.
Finally, a phenotypic analysis of NK cell-activating receptors of
peripheral blood NK cells in CRC patients indicated that these
moleculeswere significantly down-regulated as compared to those
of healthy controls. Moreover, a reduced percentage of NKG2D
and perforin-positive NK cells were associated with a poor histo-
logical grade (20). Thus, NK cell infiltration has been associated
with a favorable prognosis in only two studies. Conversely, Sandel
et al. and Halama et al. recruited 88 and 112 CRC patients, respec-
tively, and both showed that NK cell infiltration had no effect on
the clinical development of the disease (21). Therefore, the clinical
relevance of NK cell infiltration in the prognosis of CRC remains
elusive.
The sample size utilized in the aforementioned studies was
clearly very small. Thus, we investigated NK cell infiltration in
CRC by staining a tissue microarray of 1414 CRC punch biop-
sies, using CD56 or CD57 as NK cell markers. Immunohisto-
chemistry analysis indicated that 38 and 15% of punch biopsies
showed evidence of CD56+ or CD57+ cell infiltration, respec-
tively. We found that NK cell infiltration had no prognostic effect
on the clinical course of the patients. Another study found that
NK cell infiltration was not associated with mismatch repair-
deficient or mismatch repair-proficient CRC tumor status (14).
Recent studies have shown that NK cells might collaborate with
CD8+ T-cells, and that such crosstalk may initiate or intensify
an antigen-driven T-cell response. These findings prompted us to
investigate whether CRC infiltration by NK cells, in combination
with T-cells, improved the prognosis of CRC patients. NK and
T-cells were stained with biotinylated mAb specific for CD56 or
T-cell markers, such as CD3, CD4, and CD8, and these markers
were detected using immunoperoxidase methodology. Receiver
operating characteristic curve analysis identified cut-off scores
for negative (4 NK cells) and positive (>4 NK cells) CRC. NK
cells were identified in 423 of 1410 CRC tumor biopsies, but
only132 (9%) contained >4 NK cells. This study demonstrated
that the OS of CRC patients with CD56 /CD8+ cell infiltration
was significantly higher than that of patients with CD56 /CD8 
and CD56+/CD8  cell infiltration. Most importantly, patients
bearing tumors with CD56+ and CD8+ cell infiltration had the
best OS. NK cell infiltration, combined with CD3+ and CD4+
T cell and macrophage infiltration, did not appear to affect the
clinical development of the disease. In addition, two lines of
evidence suggested that CD56+ cells detected in CRC microen-
vironment belonged to an NK cell population. First, there was no
correlation between CD8+ T-cells and CD56+ cell infiltration.
Second, flow cytometry analysis of enzymatically dissociated CRC
tumor cells revealed a robust association betweenCD56+ cells and
cells expressing more specific NK cell markers, such as NKp46.
These results indicate that the presence of both NK cells and CD8
cells in the CRC microenvironment has a favorable prognostic
impact in CRC (22).
NK Cells that Escape CRC Cell-Induced
Inactivation may Shape a Proinflammatory
Tumor Microenvironment
The results of the aforementioned clinical studies raise the ques-
tion whether the mechanisms of immune evasion of CRC cells
limit the antitumor immune response. In vivo and in vitro stud-
ies have indicated that solid tumors induce both NK cell and
T-cell dysfunction by producing immunosuppressive molecules.
Published reports have shown that indoleamine 2,3-dioxygenase
and prostaglandin E2 produced by melanoma cells modify
the NK cell phenotype and impair the functions of NK cells
(23). Solid tumor cells escape NK cell recognition by utiliz-
ing transforming growth factor beta-1 (24) and lymphocyte
function-associated antigen 1 (25). This may explain the minimal
NK cell infiltration in the solid tumor microenvironment (14,
18, 25). Importantly, the immunosuppressive effects of tumor
cells may affect NK cells and T-lymphocytes, as well as their
cooperation.
To date, there is insufficient information about the contribution
of intratumoral NK cells to CRC outgrowth and progression.
However, a combination of immunohistochemistry analysis and
in vitro studies, where NK cells were cultured with CRC and
T-cells and monocytes, has provided valuable information on the
mechanisms underlying CRC cell-mediated NK cell dysfunction.
Coculture of NK cells with CRC cells (HCT116, LS-180, COLO-
205, and SW-480) induced NK cell apoptosis and CD16 down-
regulation (26). Following NK cell interaction with CRC cells,
CD16 was strongly downregulated, which was likely mediated by
metalloprotease (MMP) activation, leading to CD16 cell surface
trimming and shedding in the culture supernatant. Interestingly,
the use ofMMP inhibitors reduced CD16 antigen downregulation
and helped to prevent host immunosuppression by improving
NK cell-mediated ADCC and CD16-mediated killing of tumor
cells (27).
The mechanism by which CRC cells induce NK cell deple-
tion and apoptosis is poorly understood. However, the CD16
antigen may play a significant role in the induction of NK cell
apoptosis. In a previous study, triggering the CD16 antigen by
anti-CD16 mAbs induced a CD16 CD56+CD69+Fas+ NK cell
phenotype, as well as TNF-α production, leading to NK cell
apoptosis. Interestingly, TNF-α induced cell death failed to affect
a minor population of NK cells, which, in the presence of IL-2,
remained cytotoxic. In addition, NK cell apoptosis was abrogated
in vitro by the use of an anti-TNF-α mAb (28). Although this is
an intriguing observation, the production of TNF-α may not be
exclusively involved in the mechanism of CRC-cell-induced NK
cell apoptosis because a general caspase inhibitor failed to inhibit
HCT-116-cell-induced NK cell apoptosis. In contrast, similar to
the results described by Jewett et al., another study reported that
an NK cell population that escaped colon cancer inactivation
was CD16low/negative (25). An important question relating to the
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FIGURE 1 | CD16low NK cells surviving CRC-cell-induced dysfunction
boosted the CD8+ T-cell-dependent anti-CRC tumor immune response.
CD16high NK cell conjugation with CRC cells led to the elimination of both NK
and CRC cells. MMP activation and TNF-α production resulted in a population
of CD16low NK cells that survived cancer-cell-contact and remained functionally
active. These cells produced IFN-γ, leading to upregulation of HLA class I
antigen(s) on cancer cells. HLA class I upregulation enhanced tumor antigen
presentation to CD8+ T-cells. Conversely, the cancer cells protected
themselves from CD16low NK-cell-mediated cytotoxicity through the release of
soluble MICA/B.
FIGURE 2 | Crosstalk between NK cells and T-cells could shape a
proinflammatory immune response. Activated T-cells produced IL-2, and
CRC cells produced HMGB1. IL-2 and HMGB1 in combination activated NK
cells to produce leptin and IFNγ. The latter induced de novo expression of HLA
class II antigens by CRC cells. HLA class II antigens, presumably by interacting
with the CD4 antigen, may promote IL-6 production by macrophages. Leptin
may then directly stimulate macrophages to produce IL-1β, which then
stimulates T-cells to synthesize IL-6.
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role of a proinflammatory microenvironment in improving the
clinical course of CRC is whether CD16 /CD56+ NK cells are
involved in bidirectional crosstalk with CRC cells and CD8+
T-cells. Emerging data suggest that NK cells interact with cancer
cells and cellular components of the immune system, including
dendritic cells, macrophages, and T-cells. Available clinical data
strongly suggest that NK cells, unlike T-cells, may not represent
a major anticancer cell population. Alternatively, NK cells could
have an immunoregulatory function, possibly by shaping a proin-
flammatory CRC microenvironment supporting CD8+ T-cells.
Twomechanisms may account for the immunoregulatory proper-
ties of NK cells. The first involves CD16low/negative CD56+ NK cells
that survive CRC-cell-induced apoptosis. These cells can synthe-
size and release IFN-γ in the CRC microenvironment. IFN-γ can
induce upregulation of HLA class I antigens in CRC cells, enhanc-
ing CRC antigen presentation to CD8+ cytotoxic T-lymphocytes,
which, in turn, may eliminate CRC cells (Figure 1). The sec-
ond suggests crosstalk between activated T-cells and CRC cells.
Activated T-cells produce IL-2. IL-2 and the high mobility group
box (HMGB)1 (29) released by CRC cells stimulate NK cells to
produce IFNγ and leptin (30). IFNγ induces HLA class II antigen
expression in CRC cells. The interaction of HLA-class II antigens
withmacrophages, in the presence of leptin, triggers macrophages
to secrete IL-1β (31). IL-1β induces IL-6 synthesis and release by
T-lymphocytes, contributing to proinflammatory polarization of
the tumor microenvironment a (32) (Figure 2).
Concluding Remarks
Although the clinical role of NK cells remains controversial, the
observation that NK cells seems to support the anti-CRC activity
of CD8 T-lymphocytes highlights the need formore studies in this
area. To this end, investigatorsmust define advanced experimental
strategies aimed at (i) unveiling details about the phenotype and
function of intratumoral NK cells, (ii) investigating how NK cells
crosstalk with T-cells, and (iii) identifying ways to inhibit CRC
cell-induced NK cell dysfunction. The accomplishment of these
tasks will be critical for the development of successful NK cell-
based immunotherapy for CRC.
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